All In Biotech

Drug Trial Radar · NCT04335604

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

An Open-label, Dose-finding, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile of NOV140201 (JPI-547), a Dual Inhibitor of PARP/TNK in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Dec 6, 2017

Primary completion

Dec 14, 2021

Study completion Dec 14, 2021

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Jeil Pharmaceutical Co., Ltd.
First posted
Apr 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

Conditions

  • Advanced Solid Tumors

Interventions

  • JPI-547Drug

    The dose levels will be escalated following a 3+3 dose escalation scheme.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT) and Maximum tolerated dose (MTD)Time frame: 21days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University College of Medicine

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.